Market News

Global Cardiac Implantable Electronic Device Market- Key Developments

In February 2022, Medtronic, a medical technology company that engages in the development, manufacturing, distribution, and sale of device-based medical therapies, announced that the Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters are the first and only ablation catheters approved by the U.S. Food and Drug Administration in August 2020 (FDA) to treat the growing prevalence of pediatric atrioventricular nodal reentrant tachycardia (AVNRT).

In January 2021, Boston Scientific Corporation or its affiliates, a pioneer in providing medical devices for less invasive surgical procedures, announced that it had entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company that offers a full portfolio of mobile cardiac health solutions and services ranging from ambulatory cardiac monitors including short and long-term Holter monitors, and cardiac event monitors and mobile cardiac telemetry. The transaction includes a US$ 925 million upfront cash payment and a potential US$ 300 million commercial milestone payment.

In January 2022, Medtronic, a medical technology company that engages in the development, manufacturing, distribution, and sale of device-based medical therapies, announced it had received approval from Japan's Ministry of Health, Labor and Welfare for the sale and reimbursement of the Micra AV Transcatheter Pacing System (TPS). This approval expands the number of patients in Japan, one of the largest markets in the world, who are eligible to receive the Micra TPS, the world's smallest pacemaker. The Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart (the atria and the ventricle) are impaired.

In January 2020, Medtronic, a medical technology company that engages in the development, manufacturing, distribution, and sale of device-based medical therapies announced it had received CE (Conformité Européenne) Mark for its cobalt and crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D). ICDs monitors heart rhythms and deliver therapy to correct heart rates that are too fast, and can lead to sudden cardiac arrest. CRT-Ds, a treatment option for some individuals with heart failure, sends small electrical impulses to the lower chambers of the heart to help them beat in more synchronized patterns and reduce patient symptoms.